CO6761402A2 - Formulaciones inmunosupresoras - Google Patents
Formulaciones inmunosupresorasInfo
- Publication number
- CO6761402A2 CO6761402A2 CO13168667A CO13168667A CO6761402A2 CO 6761402 A2 CO6761402 A2 CO 6761402A2 CO 13168667 A CO13168667 A CO 13168667A CO 13168667 A CO13168667 A CO 13168667A CO 6761402 A2 CO6761402 A2 CO 6761402A2
- Authority
- CO
- Colombia
- Prior art keywords
- immunosuppressive
- formulations
- immunosuppressive formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11150431 | 2011-01-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6761402A2 true CO6761402A2 (es) | 2013-09-30 |
Family
ID=44022942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13168667A CO6761402A2 (es) | 2011-01-07 | 2013-07-16 | Formulaciones inmunosupresoras |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US20130273161A1 (es) |
| EP (2) | EP3590507A1 (es) |
| JP (2) | JP6111202B2 (es) |
| KR (2) | KR102166885B1 (es) |
| CN (1) | CN103458877B (es) |
| AR (2) | AR084801A1 (es) |
| AU (1) | AU2012204835B2 (es) |
| CA (1) | CA2823616C (es) |
| CL (1) | CL2013001979A1 (es) |
| CO (1) | CO6761402A2 (es) |
| CY (1) | CY1122182T1 (es) |
| DK (1) | DK2661261T3 (es) |
| EA (1) | EA026144B9 (es) |
| EC (1) | ECSP13012812A (es) |
| ES (1) | ES2751920T3 (es) |
| GT (1) | GT201300178A (es) |
| HR (1) | HRP20191842T1 (es) |
| HU (1) | HUE045612T2 (es) |
| IL (1) | IL227094B (es) |
| JO (1) | JO3619B1 (es) |
| LT (1) | LT2661261T (es) |
| MA (1) | MA34897B1 (es) |
| MX (2) | MX371290B (es) |
| MY (1) | MY161162A (es) |
| PE (1) | PE20140216A1 (es) |
| PL (1) | PL2661261T3 (es) |
| PT (1) | PT2661261T (es) |
| SG (1) | SG191286A1 (es) |
| SI (1) | SI2661261T1 (es) |
| TN (1) | TN2013000257A1 (es) |
| TW (2) | TWI610672B (es) |
| UA (1) | UA114283C2 (es) |
| WO (1) | WO2012093161A1 (es) |
| ZA (1) | ZA201304465B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102466348B1 (ko) * | 2014-04-10 | 2022-11-10 | 노파르티스 아게 | 면역억제제 제제 |
| EP3129020A1 (en) * | 2014-04-10 | 2017-02-15 | Novartis AG | S1p modulator immediate release dosage regimen |
| US20180042895A1 (en) | 2015-02-26 | 2018-02-15 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
| HRP20230253T1 (hr) * | 2015-07-03 | 2023-04-28 | Astellas Pharma Inc. | Stabilna farmaceutska kompozicija za oralnu administraciju |
| US11629124B2 (en) | 2017-03-09 | 2023-04-18 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
| JP7271517B2 (ja) | 2017-09-27 | 2023-05-11 | ノバルティス アーゲー | シポニモドを含む非経口製剤 |
| AU2018343239A1 (en) | 2017-09-29 | 2020-03-12 | Novartis Ag | Dosing regimen of siponimod |
| AU2018341154A1 (en) | 2017-09-29 | 2020-03-12 | Novartis Ag | Dosing regimen of siponimod |
| CN109908095A (zh) * | 2019-04-08 | 2019-06-21 | 肇庆学院 | 一种西尼莫德片剂及制备方法 |
| WO2021214717A1 (en) | 2020-04-23 | 2021-10-28 | Novartis Ag | Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome |
| WO2023172508A1 (en) * | 2022-03-09 | 2023-09-14 | Isp Investments Llc | Co-processed excipient composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1097619C (zh) | 1994-07-12 | 2003-01-01 | 伯温德药品服务公司 | 隔潮膜涂层组合物及其生产方法以及涂层制品 |
| AU2003277607B2 (en) * | 2002-11-07 | 2009-01-22 | Taisho Pharmaceutical Co., Ltd. | Base for oral composition and oral composition |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
| CN101820916A (zh) | 2007-10-12 | 2010-09-01 | 诺瓦提斯公司 | 包含鞘氨醇1磷酸(s1p)受体调节剂的组合物 |
| CN102186473B (zh) | 2008-08-18 | 2014-07-02 | 诺华股份有限公司 | 用于治疗周围神经病的化合物 |
| PL2676953T3 (pl) * | 2008-12-18 | 2017-09-29 | Novartis Ag | Sól hemifumaranowa kwasu 1-[4-[1-(4-cykloheksylo-3-trifluorometylobenzyloksyimino)-etylo]-2-etylobenzylo]-azetydyno-3-karboksylowego |
| CN102256941A (zh) * | 2008-12-18 | 2011-11-23 | 诺瓦提斯公司 | 新的盐 |
| KR20110112352A (ko) | 2008-12-18 | 2011-10-12 | 노파르티스 아게 | 1-（4-｛ｌ-［（ｅ）-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노］-에틸｝-2-에틸-벤질）-아제티딘-3-카르복실산의 신규한 다형체 형태 |
| MX2011006625A (es) | 2008-12-22 | 2011-09-28 | Novartis Ag | Regimen de dosificacion de un agonista de los receptores de s1p. |
-
2012
- 2012-01-05 EP EP19188018.6A patent/EP3590507A1/en active Pending
- 2012-01-05 SG SG2013047923A patent/SG191286A1/en unknown
- 2012-01-05 KR KR1020197004860A patent/KR102166885B1/ko active IP Right Grant
- 2012-01-05 CA CA2823616A patent/CA2823616C/en active Active
- 2012-01-05 KR KR1020137020755A patent/KR101951966B1/ko active IP Right Grant
- 2012-01-05 HU HUE12700262A patent/HUE045612T2/hu unknown
- 2012-01-05 PL PL12700262T patent/PL2661261T3/pl unknown
- 2012-01-05 ES ES12700262T patent/ES2751920T3/es active Active
- 2012-01-05 UA UAA201307576A patent/UA114283C2/uk unknown
- 2012-01-05 EA EA201391018A patent/EA026144B9/ru active Protection Beyond IP Right Term
- 2012-01-05 PT PT127002624T patent/PT2661261T/pt unknown
- 2012-01-05 MX MX2017007300A patent/MX371290B/es unknown
- 2012-01-05 MA MA36170A patent/MA34897B1/fr unknown
- 2012-01-05 DK DK12700262.4T patent/DK2661261T3/da active
- 2012-01-05 PE PE2013001522A patent/PE20140216A1/es active IP Right Grant
- 2012-01-05 JO JOP/2012/0005A patent/JO3619B1/ar active
- 2012-01-05 SI SI201231683T patent/SI2661261T1/sl unknown
- 2012-01-05 EP EP12700262.4A patent/EP2661261B1/en active Active
- 2012-01-05 LT LT12700262T patent/LT2661261T/lt unknown
- 2012-01-05 JP JP2013547861A patent/JP6111202B2/ja active Active
- 2012-01-05 MX MX2013007909A patent/MX357304B/es active IP Right Grant
- 2012-01-05 AU AU2012204835A patent/AU2012204835B2/en active Active
- 2012-01-05 WO PCT/EP2012/050151 patent/WO2012093161A1/en active Application Filing
- 2012-01-05 CN CN201280004869.2A patent/CN103458877B/zh active Active
- 2012-01-06 TW TW101100702A patent/TWI610672B/zh active
- 2012-01-06 TW TW104142389A patent/TWI583380B/zh active
- 2012-01-06 MY MYPI2013002251A patent/MY161162A/en unknown
- 2012-01-06 AR ARP120100047A patent/AR084801A1/es not_active Application Discontinuation
-
2013
- 2013-06-14 TN TNP2013000257A patent/TN2013000257A1/fr unknown
- 2013-06-14 US US13/917,730 patent/US20130273161A1/en not_active Abandoned
- 2013-06-18 ZA ZA2013/04465A patent/ZA201304465B/en unknown
- 2013-06-20 IL IL227094A patent/IL227094B/en active IP Right Grant
- 2013-07-05 CL CL2013001979A patent/CL2013001979A1/es unknown
- 2013-07-05 GT GT201300178A patent/GT201300178A/es unknown
- 2013-07-16 CO CO13168667A patent/CO6761402A2/es unknown
- 2013-08-07 EC ECSP13012812 patent/ECSP13012812A/es unknown
-
2017
- 2017-03-13 JP JP2017047220A patent/JP6324569B2/ja active Active
-
2019
- 2019-10-11 HR HRP20191842TT patent/HRP20191842T1/hr unknown
- 2019-10-22 CY CY20191101097T patent/CY1122182T1/el unknown
-
2020
- 2020-02-28 US US16/804,926 patent/US20200199069A1/en not_active Abandoned
-
2021
- 2021-04-14 US US17/230,175 patent/US20220064110A1/en active Pending
-
2022
- 2022-01-17 AR ARP220100086A patent/AR124662A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2744810T4 (da) | Tenofovir-alafenamid-hemifumarat | |
| BR112014002399A2 (pt) | conjunto | |
| DK2769050T3 (da) | Propsensor | |
| CO6801637A2 (es) | Formulaciones de anticuerpos | |
| BR112014000879A2 (pt) | deflegmador | |
| CO6761402A2 (es) | Formulaciones inmunosupresoras | |
| DK3072505T3 (da) | Testosteronformuleringer | |
| DK3272861T3 (da) | Alpha-galactosidase-sammensætninger | |
| CO6960543A2 (es) | 2-tiopirimidinonas | |
| DE102011100082A8 (de) | Traygreifvorrichtung | |
| BR112014000015A2 (pt) | formulação | |
| FI20116167L (fi) | Järjestely | |
| DK3141251T3 (da) | Koloskopi - forberedelse | |
| DK2672817T3 (da) | Forbedrede insekticide formuleringer | |
| DE112012000958A5 (de) | Handsäge | |
| DK2476953T3 (da) | Fluidbedkedel | |
| DE112012002458A5 (de) | Hydrotransformator | |
| DE112012000819A5 (de) | Gurtbandfänger | |
| DE112012005313A5 (de) | Leuchtbild | |
| DK2526750T3 (da) | Høbjærgningsmaskine | |
| DE112012001294T8 (de) | Umspritzungsverfahren | |
| FI10522U1 (fi) | Sihti | |
| FI9608U1 (fi) | Formulaatiot | |
| DE102011117169A8 (de) | Absetzplattenanordnung | |
| DK2598472T3 (da) | Formuleringer |